0001601830-24-000059.txt : 20240517 0001601830-24-000059.hdr.sgml : 20240517 20240517191221 ACCESSION NUMBER: 0001601830-24-000059 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240515 FILED AS OF DATE: 20240517 DATE AS OF CHANGE: 20240517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Marriott Tina CENTRAL INDEX KEY: 0001856414 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 24961977 MAIL ADDRESS: STREET 1: C/O RECURSION PHARMACEUTICALS STREET 2: 41 S. RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER NAME: FORMER CONFORMED NAME: Larson Tina Marriott DATE OF NAME CHANGE: 20210412 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 wk-form4_1715987524.xml FORM 4 X0508 4 2024-05-15 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001856414 Marriott Tina 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 0 1 0 0 President and COO 0 Class A Common Stock 2024-05-15 4 F 0 9998 10.01 D 533233 D Stock Option (Right to Buy) 1.06 2028-07-22 Class A Common Stock 0 485000 D Stock Option (Right to Buy) 8.55 2033-02-01 Class A Common Stock 0 434122 D Stock Option (Right to Buy) 11.40 2032-02-04 Class A Common Stock 0 159226 D Stock Option (Right to Buy) 11.40 2022-02-04 2032-02-04 Class A Common Stock 0 4784 D Stock Option (Right to Buy) 2.48 2030-12-30 Class A Common Stock 0 150000 D Stock Option (Right to Buy) 10.09 2034-02-09 Class A Common Stock 0 447917 D Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. /s/Jonathan Golightly, attorney-in-fact 2024-05-17